Trials / Completed

CompletedNCT00044759

Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

A Randomized, Open-Label, Multi-Center, Comparative Study of the Efficacy and Safety of Piperacillin/Tazobactam to Cefepime for the Empiric Treatment of Neutropenic Fever in Patients With a Hematologic Malignancy or Lymphoma

Status: Completed
Phase: Phase 3
Study type: Interventional
Enrollment: —

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.

Conditions

Hematologic Neoplasms

Interventions

Type	Name	Description
DRUG	Piperacillin/Tazobactam (Tazocin)

Timeline

Completion: 2003-01-01
First posted: 2002-09-06
Last updated: 2007-10-10

Locations

36 sites across 2 countries: United States, Canada

Source: ClinicalTrials.gov record NCT00044759. Inclusion in this directory is not an endorsement.